STRASBOURG, France, October 1 /PRNewswire-FirstCall/ -- Transgene S.A. (Eurolist Paris: FR0005175080) announces today that the first patients have been enrolled in a Phase I trial in Canada of its therapeutic vaccine candidate TG4040 (MVA-HCV). The trial is expected to treat approximately 24 patients that are chronically infected with the Hepatitis C Virus (HCV) and who have relapsed after standard treatment of Ribavirin and Pegylated-Interferon Alpha. The trial is sponsored by the University of Montreal and supported by the Canadian Network for Vaccines and Immunotherapies.
